Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
6/3/2026, 12:00:00 AM
Johnson & Johnson announced on June 3, 2026, that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase 2 JASMINE study for SLE; positive clinical data for a major pipeline candidate is estimated to have a 5-10% market impact, expected.
Korean Translation
2026년 6월 3일, Johnson & Johnson은 니포칼리맙의 2상 JASMINE 연구에서 1차 평가변수를 충족했다고 발표함. 주요 파이프라인의 긍정적인 임상 데이터는 5-10%의 시장 영향을 미칠 것으로 예상됨.
Related Recent Events
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
United Laboratories International Holdings Ltd (3933) · Other
The Annual General Meeting is scheduled for June 23, 2026, to vote on financial statements and a potential 20% share issuance mandate which could dilute existing shareholdings; high importance due to potential dilution, scheduled.
6/23/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.
6/19/2026, 12:00:00 AM